A5053650993- Lung Cancer Treatments and Mutations
- Global Cancer Incidence and Screening
- Colorectal Cancer Screening and Detection
- Lung Cancer Diagnosis and Treatment
- Retinal Diseases and Treatments
- Glaucoma and retinal disorders
- Intraocular Surgery and Lenses
- Lung Cancer Research Studies
- Health Systems, Economic Evaluations, Quality of Life
- Opioid Use Disorder Treatment
- Primary Care and Health Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Pain Management and Opioid Use
- Retinal Imaging and Analysis
- Bladder and Urothelial Cancer Treatments
- Healthcare Policy and Management
- Urinary Bladder and Prostate Research
- Economic and Financial Impacts of Cancer
- Hernia repair and management
- Gastric Cancer Management and Outcomes
- Kidney Stones and Urolithiasis Treatments
- Cancer survivorship and care
- Cardiovascular Syncope and Autonomic Disorders
- Retinal and Optic Conditions
- Suicide and Self-Harm Studies
Queen's University
2016-2025
University of Toronto
2008-2023
St. Michael's Hospital
2017-2023
Health Solutions (Sweden)
2023
Centre for Addiction and Mental Health
2023
Institute for Clinical Evaluative Sciences
2013-2022
Queens University
2020
Entomological Society of Canada
2019
Canadians Living with HIV
2017
University of Ottawa
2017
A clinical trial that compared erlotinib with a placebo for non–small-cell lung cancer demonstrated survival benefit erlotinib. We used tumor-biopsy samples from participants in this to investigate whether responsiveness and its impact on were associated expression by the tumor of epidermal growth factor receptor (EGFR) EGFR gene amplification mutations.
To evaluate the effect of KRAS and epidermal growth factor receptor (EGFR) genotype on response to erlotinib treatment in BR.21, placebo-controlled trial.We analyzed 206 tumors for mutation, 204 EGFR 159 gene copy by fluorescent situ hybridization (FISH). We reanalyzed deletion/mutation using two highly sensitive techniques that detect abnormalities samples with 5% 10% tumor cellularity. mutation was direct sequencing.Thirty patients (15%) had mutations, 34 (17%) exon 19 deletion or 21 L858R...
Purpose p53 and RAS are multifunctional proteins that critical to cell cycle regulation, apoptosis, survival, gene transcription, response stress, DNA repair. We have evaluated the prognostic predictive value of gene/protein aberrations using tumor samples from JBR.10, a North American phase III intergroup trial randomly assigned 482 patients with completely resected stage IB II non–small-cell lung cancer (NSCLC) receive four cycles adjuvant cisplatin plus vinorelbine or observation alone....
This double-blind randomized phase II trial examined whether vandetanib, an inhibitor of vascular endothelial and epidermal growth factor receptors, could prolong progression-free survival in responding patients with small-cell lung cancer.Eligible complete response (CR) or partial (PR) to combination chemotherapy (+/- thoracic prophylactic cranial radiation) received oral vandetanib 300 mg/d matched placebo. With 100 77 events, the study had 80% power detect improvement median from 4 6.5...
The "obesity paradox" reflects an observed relationship between obesity and decreased morbidity mortality, suggesting improved health outcomes for obese individuals. Studies examining the high body mass index (BMI) adverse after cardiac surgery have reported conflicting results.The study population (N=78 762) was comprised of adult patients who had undergone first-time coronary artery bypass (CABG) or combined CABG/aortic valve replacement (AVR) from April 1, 1998 to October 31, 2011 in...
High class III beta-tubulin (bTubIII) expression in advanced non-small cell lung cancer is known to correlate with reduced response rates and inferior survival anti-microtubule agents. JBR.10 showed a 12% 15% improvement 5-year recurrence-free (RFS) overall (OS), respectively, the addition of cisplatin vinorelbine following resection stage IB-II cancer. We sought determine effect bTubIII on patient outcome benefit from adjuvant chemotherapy trial.We did semiquantitative immunohistochemical...
<b>Objective</b> To assess the risk of systemic adverse events associated with intravitreal injections vascular endothelial growth factor inhibiting drugs. <b>Design</b> Population based nested case-control study. <b>Setting</b> Ontario, Canada. <b>Participants</b> 91 378 older adults a history physician diagnosed retinal disease identified between 1 April 2006 and 31 March 2011. Cases were 1477 patients admitted to hospital for ischaemic stroke, 2229 an acute myocardial infarction, 1059 or...
Adjuvant chemotherapy for early stage non-small-cell lung cancer (NSCLC) is now the standard of care, but there little information regarding its impact on quality life (QOL). We report QOL results JBR.10, a North American, intergroup, randomized trial adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC.QOL was assessed European Organisation Research Treatment Cancer Quality Life Questionnaire C30 trial-specific...
To evaluate patterns of care for age-related macular degeneration following the introduction vascular endothelial growth factor inhibitors.Using a population-based retrospective design, we studied monthly fee claims intravitreal injections submitted to Ontario Health Insurance Plan between January 1, 2000, and March 30, 2008, linked procedures physicians who performed them. This database records physician services provided as part universal health insurance coverage in Ontario, Canada....
Increased risk of cardiac failure with α-blockers in hypertension studies and 5-alpha reductase inhibitors prostate have raised safety concerns for long term management benign prostatic hyperplasia. The objective this study was to determine if these medications are associated an increased routine care.This population based used administrative databases including all men over 66 a diagnosis hyperplasia between 2005 2015. Men were categorized on inhibitor exposure and/or α-blocker primary...
Grade 4 glioma is the most common and fatal primary malignant brain tumor in adults. We sought to describe evolution of patient care survival glioblastoma patients a single-payer Canadian provincial healthcare system over 24-year period. Adult >18 years age with pathologically or clinically diagnosed (based on 4th earlier edition WHO classification) Ontario between 1994 2018 were identified followed until death study endpoint two through administrative health data. Patient characteristics,...
Abstract This is a prospective cohort study using population‐level administrative data to describe the scope of pressure ulcers in terms its prevalence, incidence risk, associating factors and extent which best practices were applied across spectrum health care settings. The for this includes information Ontario residents who admitted acute care, home long term or continuing whose contained resident assessment instrument‐minimum set ( RAI‐MDS ) outcomes better HOBIC database from 2010 2013....
In Canada, clinical practice guidelines recommend breast cancer screening, but there are gaps in adherence to recommendations for particularly among certain hard-to-reach populations, that may differ by province. We compared stage of diagnosis, proportion screen-detected cancers, and length diagnostic interval immigrant women versus long-term residents BC Ontario. conducted a retrospective cohort study using linked administrative databases identified all residing either province who were...
Summary In a prospective study of 150 patients randomly assigned to three groups, we have compared the incidence and duration sore throat after standard anaesthetic regimen using different methods airway management: facemask; laryngeal mask, mask with insertion aid. The aid is currently being developed by Portex Ltd intended both facilitate accurate placement reduce trauma during insertion. All were women undergoing short operative procedures requiring minimal postoperative analgesia. was...
To evaluate the effectiveness of prophylactic dexamethasone for control radiation induced emesis (RIE) when added to ondansetron during days 1 5 fractionated radiotherapy. The study had two hypotheses: and could provide superior RIE over alone period and; combination sustained subsequent fractions radiotherapy.Between May 2001 Jan 2004, 211 patients receiving radiotherapy (> or = 15 fractions) upper abdomen were randomly assigned receive 8 mg bid with either 4 daily placebo 5. Rescue...
7005 Background: BR.21 demonstrated a significant survival benefit for patients with advanced non-small cell lung cancer (NSCLC) who received erlotinib vs. placebo (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.58–0.85, p<0.001). Tyrosine kinase (TK) domain mutations and high EGFR gene copy number by fluorescent in situ hybridization (FISH) have been associated significantly higher response rates to erlotinib, while is better predictor of than mutations. K-ras mutation has...